ECSP19033211A - ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS - Google Patents

ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS

Info

Publication number
ECSP19033211A
ECSP19033211A ECSENADI201933211A ECDI201933211A ECSP19033211A EC SP19033211 A ECSP19033211 A EC SP19033211A EC SENADI201933211 A ECSENADI201933211 A EC SENADI201933211A EC DI201933211 A ECDI201933211 A EC DI201933211A EC SP19033211 A ECSP19033211 A EC SP19033211A
Authority
EC
Ecuador
Prior art keywords
antibodies
present
provides
methods
nucleic acids
Prior art date
Application number
ECSENADI201933211A
Other languages
English (en)
Inventor
Sandip Panicker
Graham Parry
Nancy E Stagliano
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of ECSP19033211A publication Critical patent/ECSP19033211A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos que se enlazan de una forma específica con el componente de la vía del complemento C1s. La presente invención proporciona ácidos nucleicos que comprenden las secuencias de nucleótidos que codifican los anticuerpos anti–C1s; y las células huéspedes que comprenden los ácidos nucleicos. La presente invención proporciona composiciones que comprenden los anticuerpos anti–C1s. La presente invención proporciona los métodos de uso de los anticuerpos anti–C1s.
ECSENADI201933211A 2016-10-12 2019-05-10 ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS ECSP19033211A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662407390P 2016-10-12 2016-10-12

Publications (1)

Publication Number Publication Date
ECSP19033211A true ECSP19033211A (es) 2019-07-31

Family

ID=61906346

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201933211A ECSP19033211A (es) 2016-10-12 2019-05-10 ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS

Country Status (23)

Country Link
US (2) US20200048332A1 (es)
EP (1) EP3525583A4 (es)
JP (3) JP7069138B2 (es)
KR (2) KR20240025715A (es)
CN (2) CN116554320A (es)
AR (1) AR110677A1 (es)
AU (2) AU2017341766A1 (es)
BR (1) BR112019007309A2 (es)
CA (1) CA3040253A1 (es)
CL (1) CL2019000975A1 (es)
CO (1) CO2019004741A2 (es)
CR (1) CR20190223A (es)
DO (1) DOP2019000085A (es)
EA (1) EA201990884A1 (es)
EC (1) ECSP19033211A (es)
IL (2) IL308156A (es)
MX (1) MX2019004259A (es)
PE (1) PE20191031A1 (es)
PH (1) PH12019500789A1 (es)
SG (1) SG11201903012RA (es)
TN (1) TN2019000109A1 (es)
TW (1) TWI773695B (es)
WO (1) WO2018071676A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
HUE061076T2 (hu) 2015-04-06 2023-05-28 Bioverativ Usa Inc Humanizált anti-C1s ellenanyagok alkalmazási eljárások
US11242382B2 (en) * 2020-04-20 2022-02-08 Genzyme Corporation Humanized anti-complement factor Bb antibodies
WO2022031978A1 (en) * 2020-08-06 2022-02-10 Bioverativ Usa Inc. Inflammatory cytokines and fatigue in subject with a complement mediated disease
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof
WO2023245048A1 (en) 2022-06-15 2023-12-21 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
US20240025978A1 (en) 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
EP1285960A3 (en) 1994-12-09 2003-05-07 Imperial College Innovations Limited Virulence genes from Salmonella typhimurium
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
IL129017A0 (en) 1996-10-17 2000-02-17 Oxford Biomedica Ltd Retroviral vectors
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
WO2003042361A2 (en) 2001-11-09 2003-05-22 Government Of The United States Of America, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US9715692B1 (en) 2003-04-11 2017-07-25 Facebook, Inc. System for managing bids for pay-per-click search engines
JP2007512846A (ja) * 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
EP2360186B1 (en) * 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007004670A1 (ja) 2005-07-05 2007-01-11 Kaneka Corporation メタクリル系樹脂組成物
FR2897868B1 (fr) * 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
RU2457252C2 (ru) 2006-06-21 2012-07-27 Амстердам Молекьюла Терапьютикс (Амт) Ип Б.В. AAV ВЕКТОРЫ С УСОВЕРШЕНСТВОВАННЫМИ Rep-КОДИРУЮЩИМИ ПОСЛЕДОВАТЕЛЬНОСТЯМИ, ИСПОЛЬЗУЕМЫМИ В СИСТЕМАХ ПРОДУКЦИИ НА ОСНОВЕ КЛЕТОК НАСЕКОМЫХ
WO2009020640A2 (en) * 2007-08-08 2009-02-12 Swarmcast, Inc. Media player plug-in installation techniques
EP3153524A1 (en) * 2008-12-03 2017-04-12 Genmab A/S Antibody variants having modifications in the constant region
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2014119969A1 (ko) * 2013-01-31 2014-08-07 서울대학교 산학협력단 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
LT2999714T (lt) * 2013-05-23 2020-07-10 Broteio Pharma B.V. Surišančios molekulės, kurios suriša žmogaus komplemento faktorių c2 ir jų panaudojimas
WO2015006507A1 (en) * 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
HUE061076T2 (hu) * 2015-04-06 2023-05-28 Bioverativ Usa Inc Humanizált anti-C1s ellenanyagok alkalmazási eljárások

Also Published As

Publication number Publication date
JP2024038319A (ja) 2024-03-19
EP3525583A4 (en) 2020-06-10
EA201990884A1 (ru) 2019-10-31
JP2020502996A (ja) 2020-01-30
CN110300520A (zh) 2019-10-01
AR110677A1 (es) 2019-04-24
US20200048332A1 (en) 2020-02-13
TN2019000109A1 (en) 2020-10-05
BR112019007309A2 (pt) 2019-07-02
TWI773695B (zh) 2022-08-11
SG11201903012RA (en) 2019-05-30
PH12019500789A1 (en) 2019-07-29
TW201821437A (zh) 2018-06-16
IL265957B1 (en) 2023-12-01
MX2019004259A (es) 2019-09-27
CR20190223A (es) 2019-08-21
IL265957B2 (en) 2024-04-01
IL265957A (en) 2019-05-30
CL2019000975A1 (es) 2019-10-04
PE20191031A1 (es) 2019-08-05
KR102638884B1 (ko) 2024-02-22
CA3040253A1 (en) 2018-04-19
JP2022105114A (ja) 2022-07-12
CO2019004741A2 (es) 2019-07-31
JP7420864B2 (ja) 2024-01-23
AU2022205174A1 (en) 2022-09-29
WO2018071676A1 (en) 2018-04-19
KR20240025715A (ko) 2024-02-27
TW202246327A (zh) 2022-12-01
KR20190082783A (ko) 2019-07-10
DOP2019000085A (es) 2019-07-31
AU2017341766A1 (en) 2019-05-23
EP3525583A1 (en) 2019-08-21
CN116554320A (zh) 2023-08-08
JP7069138B2 (ja) 2022-05-17
IL308156A (en) 2023-12-01
CN110300520B (zh) 2022-10-04
US20240076363A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
ECSP19033211A (es) ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CO2017011238A2 (es) Anticuerpos anti-c1s humanizados
BR112017003582A2 (pt) anticorpos, composições e usos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
JOP20220242A1 (ar) أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3
CO2017000300A2 (es) Moléculas con especificidad para cd45 y cd79
BR112019012343A2 (pt) anticorpos il-11ra
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112017012679A2 (pt) compostos imunomoduladores, seus usos, composição e kit
EA201692370A1 (ru) КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
CL2019000033A1 (es) Variantes de xilanasa y polinucleótidos que las codifican.
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
EA201500943A1 (ru) Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
CL2017000152A1 (es) Derivados de isoindolinona
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
CL2017003311A1 (es) Proteínas de fijación multiespecífica.
AR104923A1 (es) SPODOPTERA FRUGIPERDA RESISTENTE A Vip3A
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA201690383A1 (ru) НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ
EA201790969A1 (ru) Способы и композиции для безопасного и эффективного тромболизиса
CL2018000201A1 (es) Potenciamiento de la respuesta inmunológica en especies acuáticas